Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection

• Published in: Transplantation Vol. 52; no. 3; p. 530
• Main Authors: Dalmasso, A P, Vercellotti, G M, Platt, J L, Bach, F H
• Format: Journal Article
• Language: English
• Published: United States 01.09.1991
• Subjects: Animals; CD55 Antigens; Complement Inactivator Proteins - pharmacology; Complement System Proteins - physiology; Cytotoxicity, Immunologic - drug effects; Dose-Response Relationship, Drug; Endothelium - immunology; Endothelium - pathology; Graft Rejection; Humans; Membrane Proteins - metabolism; Membrane Proteins - pharmacology; Swine; Transplantation, Heterologous
• ISSN: 0041-1337
• DOI: 10.1097/00007890-199109000-00029

Complement plays a major role in hyperacute rejection of discordant xenografts. In immediately vascularized xenografts, such as porcine organs to humans, C activation contributes to triggering of endothelial cell activation and adhesion of leukocytes and platelets to the endothelial cells, which is followed by thrombosis and tissue necrosis. We investigated the potential utility of the membrane-associated inhibitor of C, decay accelerating factor (DAF), in the prevention of C-mediated tissue injury. We used an in vitro model of xenotransplantation consisting of porcine aortic endothelial cells incubated with human serum as the source of xenogeneic natural antibodies and C. Because C inhibitors such as DAF may be relatively species-specific, we tested whether human DAF would incorporate into porcine endothelial cells and function to inhibit cytotoxicity of such cells by human C. We found that purified radiolabeled human DAF incorporated into porcine endothelial cells in a dose-dependent manner and that human DAF very significantly protected the endothelial cells from the cytotoxic effect of human C.